Drug
Belantamab mafodotin clinical trials
Also written GSK2857916 and Blenrep.
- studies test it
- 53
- open now
- 17
- in phase 3
- 9
- first study started
- 2014
Keep track of what changes. Save the belantamab mafodotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
53 studies that test it; most in 2021 (13)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 13 |
| 2022 | 10 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 27
- Phase 2
- 34
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 28
GlaxoSmithKline (25) · M.D. Anderson Cancer Center (3) · PETHEMA Foundation (2) · Hellenic Society of Hematology (2) · Canadian Myeloma Research Group (1) · Roswell Park Cancer Institute (1) · University of Pennsylvania (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Dexamethasone (13) · Pomalidomide (8) · Lenalidomide (4) · Nirogacestat (4) · Bortezomib (3) · Carfilzomib (2) · Isatuximab (2) · Venetoclax (2)
Studies
Open first, then newest update. How each study uses belantamab mafodotin is read from its arms, and is right about nine times in ten.
Testing it · 53
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingPhase 2University of ChicagoNCT05789303Written as Belantamab mafodotin
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingPhase 2Emory UniversityNCT05208307Written as Belantamab Mafodotin
- Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT05145816Written as Belantamab mafodotin 2.5 mg/kg (8 weeks)
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingPhase 1/2GlaxoSmithKlineNCT05714839Written as Belantamab mafodotin
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Arm A: Belantamab Mafodotin
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05091372Written as Belantamab mafodotin
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingPhase 2Polish Myeloma ConsortiumNCT07748689Written as Belantamab Mafodotin
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingPhase 1Montefiore Medical CenterNCT07720843Written as Belantamab mafodotin
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingPhase 2GlaxoSmithKlineNCT07224672Written as Belantamab mafodotin
- Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaRecruitingPhase 2Mayo ClinicNCT05847569Written as Belantamab Mafodotin
- Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 2GlaxoSmithKlineNCT07614360Written as Belantamab mafodotin
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT05055063Written as Belantamab mafodotin
- A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingPhase 1GlaxoSmithKlineNCT07609706Written as Belantamab mafodotin
- Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingPhase 1/2Universitätsklinikum Hamburg-EppendorfNCT05853965Written as Belantamab mafodotin, Venetoclax
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingPhase 3GlaxoSmithKlineNCT06679101Written as Belantamab mafodotin
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Massachusetts General HospitalNCT05922501Written as Belantamab mafodotin
- A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPYNot yet recruitingPhase 2Hellenic Society of HematologyNCT07019545Written as Belantamab Mafodotin
- Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexActive, not recruitingPhase 1/2Canadian Myeloma Research GroupNCT03715478Written as GSK2857916 with Pomalidomide and Dexamethasone
- Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT04876248Written as Belantamab Mafodotin
- Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple MyelomaActive, not recruitingPhase 2University of PennsylvaniaNCT04680468Written as Belantamab mafodotin
See all 53 studies that test belantamab mafodotin →
Given in every arm · 14 — belantamab mafodotin is usual care beside what is tested
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolRecruitingPhase 1/2SanofiNCT04643002Written as Belantamab mafodotin
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingPhase 1Canadian Myeloma Research GroupNCT07831122Written as Belamaf
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingPhase 2GlaxoSmithKlineNCT07227311Written as Belantamab mafodotin
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Belantamab Mafodotin
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingPhase 1/2Hellenic Society of HematologyNCT05280275Written as Belantamab Mafodotin-Blmf
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingPhase 1/2Hellenic Society of HematologyNCT05573802Written as Belantamab Mafodotin-Blmf
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingPhase 1/2Hellenic Society of HematologyNCT05581875Written as Belantamab Mafodotin-Blmf
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple MyelomaSuspendedPhase 1/2Alliance for Clinical Trials in OncologyNCT06232044Written as Belantamab Mafodotin
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Belantamab mafodotin
- An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedPhase 1GlaxoSmithKlineNCT03828292Written as Belantamab mafodotin
- Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaTerminatedPhase 1Mayo ClinicNCT04892264Written as Belantamab Mafodotin
- To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedPhase 1/2GlaxoSmithKlineNCT03544281Written as Belantamab mafodotin
- Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedPhase 1/2GlaxoSmithKlineNCT03848845Written as belantamab mafodotin
- Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnPhase 1/2Hackensack Meridian HealthNCT05493618Written as Belantamab mafodotin
As the comparator · 1 — what is tested is compared with belantamab mafodotin
Codes
What other systems call belantamab mafodotin · ClinicalTrials.gg INT001113
- MeSH (NLM) C000631691belantamab mafodotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DB1041CXDGBELANTAMAB MAFODOTINConfirmed FDA, NLM, Wikidata
- Wikidata Q98139657belantamab mafodotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114299Belantamab MafodotinOne source FDA
- DrugBank DB15719One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631691 | belantamab mafodotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DB1041CXDG | BELANTAMAB MAFODOTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q98139657 | belantamab mafodotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114299 | Belantamab Mafodotin | One source FDA |
| DrugBank | DB15719 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.